In contrast, among non‐CBF‐rearranged AML patients, CSF3Rmut patients had markedly worse median OS and PFS (OS: 20.1 vs. not reached, p = 0.0007; PFS: 8.8 vs. not reached, p < 0.0001) (Figure 5B). This evidence concerns the gene CEBPZ and acute myeloid leukemia.